Economic evaluation of the screening for Alzheimer’s disease in China
BackgroundWe evaluated the cost-effectiveness of the screening in mainland China for Alzheimer’s disease (AD) patients aged over 60.MethodsIndividuals in mainland China, received an initial screening by questionnaire on mental state, and those with scores deemed suspicious for AD were referred to di...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Aging Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2022.968842/full |
| _version_ | 1798000404802306048 |
|---|---|
| author | Yinan Ren Yinan Ren Dachuang Zhou Dachuang Zhou Qian Xing Qian Xing Fangfang Gong Wenxi Tang Wenxi Tang |
| author_facet | Yinan Ren Yinan Ren Dachuang Zhou Dachuang Zhou Qian Xing Qian Xing Fangfang Gong Wenxi Tang Wenxi Tang |
| author_sort | Yinan Ren |
| collection | DOAJ |
| description | BackgroundWe evaluated the cost-effectiveness of the screening in mainland China for Alzheimer’s disease (AD) patients aged over 60.MethodsIndividuals in mainland China, received an initial screening by questionnaire on mental state, and those with scores deemed suspicious for AD were referred to diagnostic tests. A 9-state Markov model was developed to simulate the disease progression of a cohort of 100,000 subjects aging from 60 to 80. In addition, several scenarios were analyzed to assess the robustness under different screening frequency, starting age, the duration of drug effects, and the health status of subjects.ResultsThe ICER of AD screening was 26413.77 USD per QALY [quality-adjusted life-year (QALY)] compared with no screening. The number of deaths and severe AD cases who did not receive treatment averted by screening accounted for 0.076 and 0.006% of the total population, respectively, and the net monetary benefit was 128.29 USD per capita. Under the thresholds of one and three times the gross domestic product per capita, the probability of screening being cost-effective was approximately 18 and 77%, respectively. The ICER decreased to 18132.96USD per QALY when the drug effect was prolonged, and increased when the frequency of screening was increased, the starting age was postponed, and patients suffering from comorbidities were more. However, the number of severe AD cases and deaths declined when the screening frequency increased.ConclusionScreening for AD in individuals over 60 can reduce the numbers of severe AD cases and deaths and may be cost-effective, depending on factors such as screening frequency, starting age of screening, and duration of drug effects. Additionally, mild cognitive impairment (MCI) is an important stage at which the burden of progression to AD may be reduced and the cost-effectiveness of screening may be improved. |
| first_indexed | 2024-04-11T11:19:42Z |
| format | Article |
| id | doaj.art-af2965e21e9947c2b9aec00820baf3ce |
| institution | Directory Open Access Journal |
| issn | 1663-4365 |
| language | English |
| last_indexed | 2024-04-11T11:19:42Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Aging Neuroscience |
| spelling | doaj.art-af2965e21e9947c2b9aec00820baf3ce2022-12-22T04:27:06ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652022-09-011410.3389/fnagi.2022.968842968842Economic evaluation of the screening for Alzheimer’s disease in ChinaYinan Ren0Yinan Ren1Dachuang Zhou2Dachuang Zhou3Qian Xing4Qian Xing5Fangfang Gong6Wenxi Tang7Wenxi Tang8School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, ChinaCenter for Pharmacoeconomics and Outcomes Research of China Pharmaceutical University, Nanjing, ChinaSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, ChinaCenter for Pharmacoeconomics and Outcomes Research of China Pharmaceutical University, Nanjing, ChinaSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, ChinaCenter for Pharmacoeconomics and Outcomes Research of China Pharmaceutical University, Nanjing, ChinaDepartment of Hospital Group Office, Shenzhen Luohu Hospital Group Luohu People’s Hospital (The Third Affiliated Hospital of Shenzhen University), Shenzhen, ChinaSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, ChinaCenter for Pharmacoeconomics and Outcomes Research of China Pharmaceutical University, Nanjing, ChinaBackgroundWe evaluated the cost-effectiveness of the screening in mainland China for Alzheimer’s disease (AD) patients aged over 60.MethodsIndividuals in mainland China, received an initial screening by questionnaire on mental state, and those with scores deemed suspicious for AD were referred to diagnostic tests. A 9-state Markov model was developed to simulate the disease progression of a cohort of 100,000 subjects aging from 60 to 80. In addition, several scenarios were analyzed to assess the robustness under different screening frequency, starting age, the duration of drug effects, and the health status of subjects.ResultsThe ICER of AD screening was 26413.77 USD per QALY [quality-adjusted life-year (QALY)] compared with no screening. The number of deaths and severe AD cases who did not receive treatment averted by screening accounted for 0.076 and 0.006% of the total population, respectively, and the net monetary benefit was 128.29 USD per capita. Under the thresholds of one and three times the gross domestic product per capita, the probability of screening being cost-effective was approximately 18 and 77%, respectively. The ICER decreased to 18132.96USD per QALY when the drug effect was prolonged, and increased when the frequency of screening was increased, the starting age was postponed, and patients suffering from comorbidities were more. However, the number of severe AD cases and deaths declined when the screening frequency increased.ConclusionScreening for AD in individuals over 60 can reduce the numbers of severe AD cases and deaths and may be cost-effective, depending on factors such as screening frequency, starting age of screening, and duration of drug effects. Additionally, mild cognitive impairment (MCI) is an important stage at which the burden of progression to AD may be reduced and the cost-effectiveness of screening may be improved.https://www.frontiersin.org/articles/10.3389/fnagi.2022.968842/fullmild cognitive impairmentquality-adjusted life-yearincremental cost-effectiveness rationet monetary benefitmini-mental state examination |
| spellingShingle | Yinan Ren Yinan Ren Dachuang Zhou Dachuang Zhou Qian Xing Qian Xing Fangfang Gong Wenxi Tang Wenxi Tang Economic evaluation of the screening for Alzheimer’s disease in China Frontiers in Aging Neuroscience mild cognitive impairment quality-adjusted life-year incremental cost-effectiveness ratio net monetary benefit mini-mental state examination |
| title | Economic evaluation of the screening for Alzheimer’s disease in China |
| title_full | Economic evaluation of the screening for Alzheimer’s disease in China |
| title_fullStr | Economic evaluation of the screening for Alzheimer’s disease in China |
| title_full_unstemmed | Economic evaluation of the screening for Alzheimer’s disease in China |
| title_short | Economic evaluation of the screening for Alzheimer’s disease in China |
| title_sort | economic evaluation of the screening for alzheimer s disease in china |
| topic | mild cognitive impairment quality-adjusted life-year incremental cost-effectiveness ratio net monetary benefit mini-mental state examination |
| url | https://www.frontiersin.org/articles/10.3389/fnagi.2022.968842/full |
| work_keys_str_mv | AT yinanren economicevaluationofthescreeningforalzheimersdiseaseinchina AT yinanren economicevaluationofthescreeningforalzheimersdiseaseinchina AT dachuangzhou economicevaluationofthescreeningforalzheimersdiseaseinchina AT dachuangzhou economicevaluationofthescreeningforalzheimersdiseaseinchina AT qianxing economicevaluationofthescreeningforalzheimersdiseaseinchina AT qianxing economicevaluationofthescreeningforalzheimersdiseaseinchina AT fangfanggong economicevaluationofthescreeningforalzheimersdiseaseinchina AT wenxitang economicevaluationofthescreeningforalzheimersdiseaseinchina AT wenxitang economicevaluationofthescreeningforalzheimersdiseaseinchina |